WALTHAM, Mass., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will
report third quarter of 2017 financial results on Thursday, November 9, 2017. The Company will issue a press release before
the market opens and will host a conference call at 8:30 a.m. EST to discuss business updates and financial results for the 3-month
and 9-month reporting periods ended September 30, 2017.
The conference call will be accessible by dialing toll-free (800) 708-4539 for domestic callers and (847) 619-6396 for
international callers. Dial-in participants must provide the passcode 45935245. In addition, a webcast will be accessible via the
Investor Relations section of the Company’s website. Both the conference call and webcast will
be archived for a period of time following the live event. The replay dial-in numbers are (888) 843-7419 for domestic callers and
(630) 652-3042 for international callers. Replay listeners must provide the passcode 45935245#.
About Repligen Corporation
Repligen Corporation (NASDAQ:RGEN) is a global bioprocessing company that develops and commercializes highly innovative products
that deliver cost and process efficiencies to biological drug manufacturers worldwide. Our portfolio includes protein products
(Protein A affinity ligands, cell culture growth factors), chromatography products (OPUS® pre-packed columns, chromatography
resins, ELISA kits) and filtration products (XCell™ ATF systems, TangenX™ Sius™ flat sheet TFF cassettes, and Spectrum KrosFlo™
hollow fiber TFF cartridges and systems). The Protein A ligands and growth factor products that we produce are key components of
Protein A affinity resins and cell culture media, respectively. Protein A affinity resins are the industry standard for downstream
separation and purification of monoclonal antibody-based therapeutics. Growth factors are used in upstream processes to accelerate
cell growth and productivity. Our innovative line of OPUS® chromatography columns, used in downstream processes for bench-scale
through clinical-scale purification needs, are delivered pre-packed to our customers with their choice of resin and bed height. Our
XCell™ ATF Systems, available in stainless steel and single-use configurations, continuously eliminate waste from a bioreactor to
concentrate cells and significantly increase productivity in upstream processes. Single-use Sius™ TFF cassettes and hardware are
used for biologic drug concentration in downstream filtration processes. Spectrum KrosFlo™ TFF cartridges and systems are used in
both upstream and downstream filtration processes. Repligen’s corporate headquarters are in Waltham, MA (USA), with additional
administrative and manufacturing operations in Shrewsbury, MA, Rancho Dominguez, CA, Lund, Sweden and Weingarten, Germany.
This press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are
cautioned that statements in this press release which are not strictly historical statements including, without limitation,
statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “could” and similar expressions,
constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that
could cause actual results to differ materially from those anticipated, including risks discussed from time to time in our filings
with the Securities and Exchange Commission. We expressly disclaim any responsibility to update any forward-looking statements,
except as required by law.
Source:
Repligen Corporation
Sondra Newman
Senior Director Investor Relations
(781) 419-1881
snewman@repligen.com
